TransCode

Completed initial public offering of common stock, raising $28.8 million in gross proceeds

Awarded $2.3 million in funding from NIH to support clinical evaluation of TTX-MC138

On track to submit eIND application for TTX-MC138 in Q1 2022

BOSTON, August 23, 2021–(BUSINESS WIRE)–TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an